INX Inc. (NASDAQ:INXI) witnessed volume of 260,218.00 shares during last trade however it holds an average trading capacity of 164,815.00 shares. INXI last trade opened at $8.63 reached intraday low of $8.56 and went -0.58% down to close at $8.58.
Read Full Article and Disclaimer at:http://stockbling.com/8254/stock-highlights/fulsome-volume-stock-at-nasd...
INX Inc at Year Record Breaking Price - NASDAQ:INXI
INX Inc (NASDAQ:INXI) achieved its new 52 week high price of $8.63 where it was opened at $8.61 UP 0.01 points or +0.12% by closing at $8.61. INXI transacted shares during the day were over 11,892 shares however it has an average volume of 156,805 shares.
Read Full Article and Disclaimer at: http://crwewallstreetnewsalert.com/?p=6394
INX Inc Succeeded New Record Year Price - NASDAQ:INXI
INX Inc (NASDAQ:INXI) achieved its new 52 week high price of $8.61 where it was opened at $8.55 UP 1.00 points or +13.25% by closing at $8.55. INXI transacted shares during the day were over 2.13 million shares however it has an average volume of 8,885 shares.
Read Full Article and Disclaimer at: http://crwewallstreetnewsalert.com/?p=6321
ARBX, ENZ, AVOT.PK, INXI, HBAN, - Arbinet Corporation, Enzo Biochem, American Video Teleconferencing Corp., INX Inc. and Hunting
Arbinet Corporation (NASDAQ:ARBX) reported that their respective boards of directors have scheduled special meetings of their respective stockholders for Friday, February 25, 2011 to vote on matters incident to the proposed transaction announced by the companies on November 11, 2010.
Gone are the days of buy-and-hold investing. Stock picking was the strategy for the past decade, and these 10 companies were the best performers in the S&P 500.
Stock picking trumped buy-and-hold over the past decade, reversing the reigning investment strategy that encouraged investors to pile into passively managed index funds.
Source CRWESelect : CBLI, PWRM.OB, PNCL, ORFG.PK, INXI, - Cleveland BioLabs, Power3 Medical Products, Pinnacle Airlines Corp.
Cleveland BioLabs, Inc. (NASDAQ:CBLI) previously reported that CBLB502, a drug under development to treat exposure to radiation, has been granted Orphan Drug status by the U.S. Food and Drug Administration (FDA) for prevention of death following a potentially lethal dose of total body irradiation during or after a radiation disaster.